{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:20:06Z","timestamp":1783635606185,"version":"3.55.0"},"reference-count":186,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Atopic dermatitis is the most prevalent chronic inflammatory skin disease, posing a significant individual and healthcare burden. Traditionally managed with topical agents and broad immunosuppressants, the treatment landscape has shifted significantly in recent years. This review explores the transition from immunopathogenic understanding to personalized treatment strategies through advanced systemic therapies. We provide a thorough description of the current therapeutic arsenal, including approved monoclonal antibodies and Janus kinase (JAK) inhibitors, as well as experimental agents under clinical investigation. Key cytokines and receptors implicated in type 2 inflammation are explored alongside relevant intracellular signaling pathways. Special attention has been given to literature published from 2015 onwards. By synthesizing the latest scientific and clinical knowledge, this review aims to provide clinicians with practical guidance for navigating the evolving landscape of atopic dermatitis management and improving patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms262311487","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:50:13Z","timestamp":1764244213000},"page":"11487","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies"],"prefix":"10.3390","volume":"26","author":[{"given":"Alvaro","family":"Prados-Carmona","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain"},{"name":"Instituto Biosanitario de Granada, ibs.Granada, 18012 Granada, Spain"},{"name":"Escuela Internacional de Posgrado, Universidad de Granada, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7869-0206","authenticated-orcid":false,"given":"Husein","family":"Husein-ElAhmed","sequence":"additional","affiliation":[{"name":"Instituto Biosanitario de Granada, ibs.Granada, 18012 Granada, Spain"},{"name":"Department of Dermatology, Hospital de Baza, 18800 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-3671","authenticated-orcid":false,"given":"Francisco Jos\u00e9","family":"Navarro-Trivi\u00f1o","sequence":"additional","affiliation":[{"name":"Instituto Biosanitario de Granada, ibs.Granada, 18012 Granada, Spain"},{"name":"Unit of Contact Eczema and Immunoallergic Diseases, Hospital Universitario San Cecilio, 18016 Granada, Spain"},{"name":"Department of Medicine, University of Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain"},{"name":"Instituto Biosanitario de Granada, ibs.Granada, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The Translational Revolution in Atopic Dermatitis: The Paradigm Shift from Pathogenesis to Treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s13555-023-00920-4","article-title":"Emerging Systemic Treatments for Atopic Dermatitis","volume":"13","author":"Ferrucci","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Makowska, K., Nowaczyk, J., Blicharz, L., Wa\u015bkiel-Burnat, A., Czuwara, J., Olszewska, M., and Rudnicka, L. (2023). Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010781"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/ACI.0000000000000306","article-title":"The \u201comics\u201d Revolution: Redefining the Understanding and Treatment of Allergic Skin Diseases","volume":"16","author":"Oliva","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic Dermatitis","volume":"405","author":"Brunner","year":"2025","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ruiz-Villaverde, R., Cebolla-Verdugo, M., Prados-Carmona, A., Pereyra Rodr\u00edguez, J.J., and Armario-Hita, J.C. (2024). Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: Where Are We Going?. Life, 14.","DOI":"10.3390\/life14101236"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1111\/ijd.17256","article-title":"Patient and Family Burden in Pediatric Atopic Dermatitis and Its Treatment Pattern in Japan","volume":"63","author":"Otsuka","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_8","first-page":"349","article-title":"Atopic Dermatitis\u2014Perspectives and Unmet Medical Needs","volume":"21","author":"Buhl","year":"2023","journal-title":"JDDG\u2014J. Ger. Soc. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jvc2.537","article-title":"Role of Interleukins in Dermatology: Exploring the Immune Mechanisms in Skin Diseases","volume":"3","author":"Corell","year":"2024","journal-title":"JEADV Clin. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.det.2017.02.006","article-title":"An Update on the Pathophysiology of Atopic Dermatitis","volume":"35","author":"Malik","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jid.2020.05.119","article-title":"TSLP and IL-7R Variants Are Associated with Persistent Atopic Dermatitis","volume":"141","author":"Berna","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.alit.2023.01.002","article-title":"ILC2s in Skin Disorders","volume":"72","author":"Imai","year":"2023","journal-title":"Allergol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.20975","article-title":"Therapeutic Potential of Targeting Interleukin-1 Family Cytokines in Chronic Inflammatory Skin Diseases","volume":"186","author":"Calabrese","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cytogfr.2017.09.005","article-title":"Pathophysiology of IL-33 and IL-17 in Allergic Disorders","volume":"38","author":"Gupta","year":"2017","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1073\/pnas.1307321110","article-title":"Skin-Specific Expression of IL-33 Activates Group 2 Innate Lymphoid Cells and Elicits Atopic Dermatitis-like Inflammation in Mice","volume":"110","author":"Imai","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.jid.2019.04.016","article-title":"IL-33\u2013Induced Atopic Dermatitis\u2013Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils","volume":"139","author":"Imai","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.jid.2019.06.118","article-title":"ILC2s and Basophils Team Up to Orchestrate IL-33\u2013Induced Atopic Dermatitis","volume":"139","author":"Ryffel","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2015.04.047","article-title":"IL-33 and Thymic Stromal Lymphopoietin in Mast Cell Functions","volume":"778","author":"Saluja","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1084\/jem.20130351","article-title":"A Role for IL-25 and IL-33\u2013Driven Type-2 Innate Lymphoid Cells in Atopic Dermatitis","volume":"210","author":"Salimi","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/jcm4050884","article-title":"Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications","volume":"4","author":"Siegfried","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ad.2023.07.008","article-title":"Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists","volume":"114","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab Improves the Molecular Signature in Skin of Patients with Moderate-to-Severe Atopic Dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1398-9995.2011.02747.x","article-title":"Gene Expression Is Differently Affected by Pimecrolimus and Betamethasone in Lesional Skin of Atopic Dermatitis","volume":"67","author":"Jensen","year":"2012","journal-title":"Allergy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of Atopic Dermatitis with Narrow-Band UVB Phototherapy and Biomarkers for Therapeutic Response","volume":"128","author":"Tintle","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The Immunology of Atopic Dermatitis and Its Reversibility with Broad-Spectrum and Targeted Therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","first-page":"e159","article-title":"Switching from Reference Adalimumab to Biosimilar. Assessment of Clinical Outcomes in Psoriasis","volume":"62","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_28","unstructured":"Prados Carmona, A., Husein-ElAhmed, H., Navarro-Trivi\u00f1o, F., and Ruiz-Villaverde, R. (J. Dtsch. Dermatol. Ges., 2025). Deciphering Atopic Dermatitis Heterogeneity: A Short-Review on the Translational Revolution from Endotypes to Immunotypes, J. Dtsch. Dermatol. Ges., pending publication."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/all.13239","article-title":"Emerging Role of Interleukin-31 and Interleukin-31 Receptor in Pruritus in Atopic Dermatitis","volume":"73","author":"Furue","year":"2018","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kabashima, K., and Irie, H. (2021). Interleukin-31 as a Clinical Target for Pruritus Treatment. Front. Med., 8.","DOI":"10.3389\/fmed.2021.638325"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nemmer, J.M., Kuchner, M., Datsi, A., Ol\u00e1h, P., Julia, V., Raap, U., and Homey, B. (2021). Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues. Front. Med., 8.","DOI":"10.3389\/fmed.2021.639097"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/exd.13533","article-title":"Interleukin-31 and Interleukin-31 Receptor: New Therapeutic Targets for Atopic Dermatitis","volume":"27","author":"Nakashima","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/exd.14749","article-title":"Keratinocytes Activated by IL-4\/IL-13 Express IL-2R\u03b3 With Consequences on Epidermal Barrier Function","volume":"32","author":"Progneaux","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40259-018-0280-7","article-title":"Therapeutic Targeting of the Interleukin-4\/Interleukin-13 Signaling Pathway: In Allergy and Beyond","volume":"32","author":"Bitton","year":"2018","journal-title":"BioDrugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"eaaw2938","DOI":"10.1126\/sciimmunol.aaw2938","article-title":"A Key Role for IL-13 Signaling via the Type 2 IL-4 Receptor in Experimental Atopic Dermatitis","volume":"5","author":"Bitton","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cyto.2012.10.031","article-title":"IL-4 up-Regulates Epidermal Chemotactic, Angiogenic, and pro-Inflammatory Genes and down-Regulates Antimicrobial Genes in Vivo and in Vitro: Relevant in the Pathogenesis of Atopic Dermatitis","volume":"61","author":"Bao","year":"2013","journal-title":"Cytokine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jdermsci.2024.03.007","article-title":"IL-4-Induced Decrease in Both the Number and CTLA-4 Expression of Treg Impairs Suppression of Th2 Type Inflammation in Severe Atopic Dermatitis","volume":"114","author":"Wang","year":"2024","journal-title":"J. Dermatol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jia, H., Wan, H., and Zhang, D. (2023). Innate Lymphoid Cells: A New Key Player in Atopic Dermatitis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1277120"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaci.2024.06.021","article-title":"IL-4 Acts on Skin-Derived Dendritic Cells to Promote the TH2 Response to Cutaneous Sensitization and the Development of Allergic Skin Inflammation","volume":"154","author":"Das","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an Underestimated Cytokine in Atopic Dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Posadas, L., Hodges, R.R., Diebold, Y., and Dartt, D.A. (2018). Context-Dependent Regulation of Conjunctival Goblet Cell Function by Allergic Mediators. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-30002-x"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/bjo.2009.173419","article-title":"Expression of the Interleukin-4 Receptor in Human Conjunctival Epithelial Cells","volume":"94","author":"Ueta","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Junttila, I.S. (2018). Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00888"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.alit.2020.01.005","article-title":"Implications of IL-13R\u03b12 in Atopic Skin Inflammation","volume":"69","author":"Furue","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.4049\/jimmunol.1002118","article-title":"IL-13R\u03b12 Has a Protective Role in a Mouse Model of Cutaneous Inflammation","volume":"185","author":"Sivaprasad","year":"2010","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1067\/mai.2003.1383","article-title":"Cytokine Regulation of IL-13R\u03b12 and IL-13R\u03b11 in Vivo and in Vitro","volume":"111","author":"Zheng","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ulzii, D., Kido-Nakahara, M., Nakahara, T., Tsuji, G., Furue, K., Hashimoto-Hachiya, A., and Furue, M. (2019). Scratching Counteracts Il-13 Signaling by Upregulating the Decoy Receptor Il-13r\u03b12 in Keratinocytes. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133324"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1152\/ajplung.00120.2014","article-title":"Modulation of Pulmonary Fibrosis by IL-13R2","volume":"308","author":"Medina","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/cea.13478","article-title":"Chitinase 3-like 1 Drives Allergic Skin Inflammation via Th2 Immunity and M2 Macrophage Activation","volume":"49","author":"Kwak","year":"2019","journal-title":"Clin. Exp. Allergy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm1332","article-title":"IL-13 Signaling through the IL-13\u03b12 Receptor Is Involved in Induction of TGF-\u03921 Production and Fibrosis","volume":"12","author":"Strober","year":"2006","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic Dermatitis Is an IL-13\u2013Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jaci.2020.11.036","article-title":"Mast Cell\u2013Derived IL-13 Downregulates IL-12 Production by Skin Dendritic Cells to Inhibit the TH1 Cell Response to Cutaneous Antigen Exposure","volume":"147","author":"Das","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Furue, M. (2020). Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155382"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/imm.13120","article-title":"The IL-13\u2013OVOL1\u2013FLG Axis in Atopic Dermatitis","volume":"158","author":"Furue","year":"2019","journal-title":"Immunology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/all.13437","article-title":"The IL-13\/periostin\/IL-24 Pathway Causes Epidermal Barrier Dysfunction in Allergic Skin Inflammation","volume":"73","author":"Mitamura","year":"2018","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11010-016-2696-z","article-title":"MicroRNA-143 Inhibits IL-13-Induced Dysregulation of the Epidermal Barrier-Related Proteins in Skin Keratinocytes via Targeting to IL-13R\u03b11","volume":"416","author":"Zeng","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2475047","DOI":"10.1155\/2018\/2475047","article-title":"NRF2 Activation Inhibits Both Tgf- \u03b2 1- and Il-13-Mediated Periostin Expression in Fibroblasts: Benefit of Cinnamaldehyde for Antifibrotic Treatment","volume":"2018","author":"Mitamura","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.4049\/jimmunol.172.7.4068","article-title":"Protection from Fluorescein Isothiocyanate-Induced Fibrosis in IL-13-Deficient, but Not IL-4-Deficient, Mice Results from Impaired Collagen Synthesis by Fibroblasts","volume":"172","author":"Kolodsick","year":"2004","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Miake, S., Tsuji, G., Takemura, M., Hashimoto-Hachiya, A., Vu, Y.H., Furue, M., and Nakahara, T. (2019). IL-4 Augments IL-31\/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20164053"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 Immunity in the Skin and Lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1399-3038.2011.01241.x","article-title":"IL-31 Significantly Correlates with Disease Activity and Th2 Cytokine Levels in Children with Atopic Dermatitis","volume":"23","author":"Raap","year":"2012","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdermsci.2014.02.009","article-title":"Distribution of IL-31 and Its Receptor Expressing Cells in Skin of Atopic Dermatitis","volume":"74","author":"Kato","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Calabrese, L., D\u2019Onghia, M., Lazzeri, L., Rubegni, G., and Cinotti, E. (2024). Blocking the IL-4\/IL-13 Axis versus the JAK\/STAT Pathway in Atopic Dermatitis: How Can We Choose?. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070775"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: First Global Approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/ced\/llae208","article-title":"Short-, Mid- and Long-Term Efficacy of Dupilumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Multicentre Italian Study of 2576 Patients","volume":"49","author":"Ferrucci","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1111\/jdv.18805","article-title":"Treatment of Chronic Hand Eczema with Dupilumab\u2014A Retrospective Follow-up Study","volume":"37","author":"Olesen","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_67","first-page":"e335","article-title":"Pregnancy and Breastfeeding Outcome in Patients with Atopic Dermatitis Treated with Dupilumab: The Clinical Experience of Three Centers","volume":"63","author":"Farinha","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab Use in Dermatologic Conditions beyond Atopic Dermatitis\u2013a Systematic Review","volume":"32","author":"Hendricks","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ad.2024.04.010","article-title":"Dupilumab to Treat Chronic Palmoplantar Eczema: A Retrospective Multicenter Cohort Study","volume":"115","year":"2024","journal-title":"Actas Dermosifiliogr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s13555-024-01235-8","article-title":"Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study","volume":"14","author":"Torres","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1111\/jdv.19980","article-title":"Long-Term Therapeutic Response to Dupilumab in Patients Affected by Prurigo Nodularis: A Real-World Retrospective Study","volume":"38","author":"Chiricozzi","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaci.2022.12.824","article-title":"In Search of the Holy Grail in Atopic Dermatitis: Will Dupilumab Become the First Disease-Modifying Atopic Dermatitis Drug?","volume":"151","author":"Bieber","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_73","first-page":"604","article-title":"Long-Term Efficacy and Safety of Dupilumab in Adolescents with Severe Atopic Dermatitis: A 3-Year Real-Life Study","volume":"64","author":"Barei","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaad.2024.05.029","article-title":"Reduced Atopic March Risk in Pediatric Atopic Dermatitis Patients Prescribed Dupilumab versus Conventional Immunomodulatory Therapy: A Population-Based Cohort Study","volume":"91","author":"Lin","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1089\/derm.2024.0211","article-title":"Effectiveness, Safety, and Long-Term Continuation Rate Analysis of Dupilumab Treatment in Adolescents with Atopic Dermatitis: A Single-Center Real-Life Retrospective Study","volume":"36","author":"Lauletta","year":"2025","journal-title":"Dermatitis"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Olbrich, H., Sadik, C.D., Ludwig, R.J., Tha\u00e7i, D., and Boch, K. (2023). Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules, 13.","DOI":"10.3390\/biom13040634"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab Progressively Improves Systemic and Cutaneous Abnormalities in Patients with Atopic Dermatitis","volume":"143","author":"Bissonnette","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_78","first-page":"652","article-title":"Treatment of Refractory Solar Urticaria: Could Dupilumab Fill the Current Gap?","volume":"21","author":"Aguilera","year":"2023","journal-title":"JDDG\u2014J. Ger. Soc. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual Blockade of IL-4 and IL-13 with Dupilumab, an IL-4R\u03b1 Antibody, Is Required to Broadly Inhibit Type 2 Inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/all.16368","article-title":"Long-term Efficacy and Safety of Stapokibart for Moderate-to-severe Atopic Dermatitis: 52-week Results from a Phase 3 Trial","volume":"80","author":"Zhao","year":"2024","journal-title":"Allergy"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40259-024-00668-z","article-title":"Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial","volume":"38","author":"Zhao","year":"2024","journal-title":"BioDrugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s12325-024-02887-w","article-title":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis","volume":"41","author":"Zhang","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","article-title":"Efficacy and Safety of Rademikibart (CBP-201), a next-Generation MAb Targeting IL-4R\u03b1, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Trial (CBP-201-WW001)","volume":"153","author":"Silverberg","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.str.2010.01.003","article-title":"Molecular Basis for Shared Cytokine Recognition Revealed in the Structure of an Unusually High Affinity Complex between IL-13 and IL-13R\u03b12","volume":"18","author":"Lupardus","year":"2010","journal-title":"Structure"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamadermatol.2024.2131","article-title":"Cendakimab in Patients With Moderate to Severe Atopic Dermatitis","volume":"160","author":"Blauvelt","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lytvyn, Y., and Gooderham, M. (2023). Targeting Interleukin 13 for the Treatment of Atopic Dermatitis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020568"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and Safety of Lebrikizumab in Combination with Topical Corticosteroids in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase II and Phase III Trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","article-title":"American Academy of Dermatology Guidelines: Awareness of Comorbidities Associated with Atopic Dermatitis in Adults","volume":"86","author":"Davis","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","article-title":"Dupilumab in Adults With Moderate to Severe Atopic Dermatitis","volume":"160","author":"Beck","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of Infection in Patients with Atopic Dermatitis Treated with Dupilumab: A Meta-Analysis of Randomized Controlled Trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","article-title":"Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis","volume":"21","author":"Beck","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","article-title":"Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials","volume":"24","author":"Thyssen","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Li, X., Sun, Y., Liu, M., and Tang, J. (2025). Real-World Pharmacovigilance Analysis of Drug-Related Conjunctivitis Using the FDA Adverse Event Reporting System Database. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-92796-x"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12016-019-08739-8","article-title":"Immunologic Adverse Effects of Biologics for the Treatment of Atopy","volume":"59","author":"Aranez","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Prados-Carmona, A., Navarro-Trivi\u00f1o, F., Husein-ElAhmed, H., and Ruiz-Villaverde, R. (2025). Comparative Real-World Effectiveness and Safety of Biologics and JAK Inhibitors in Atopic Dermatitis: Short- and Medium-to-Long-Term Analysis from a Regional Healthcare Network in Southern Spain. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1658843"},{"key":"ref_102","first-page":"165","article-title":"Eosinophilia Induced by Blocking the IL-4\/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J. Investig. Allergy Clin. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-World Evidence of Dupilumab Efficacy and Risk of Adverse Events: A Systematic Review and Meta-Analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the Risk of Conjunctivitis and Serious Infection in Patients with Atopic Dermatitis: A Propensity Score\u2013Matched Cohort Study","volume":"84","author":"Schneeweiss","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","article-title":"Retrospective Analysis of Adverse Events with Dupilumab Reported to the United States Food and Drug Administration","volume":"84","author":"Wang","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jaci.2023.08.024","article-title":"Dupilumab Strengthens Herpes Simplex Virus Type 1\u2013Specific Immune Responses in Atopic Dermatitis","volume":"152","author":"Traidl","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the Atopic March: Meta-Analysis of the Dupilumab Atopic Dermatitis Database for Incident Allergic Events","volume":"151","author":"Geba","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"158","DOI":"10.18176\/jiaci.0906","article-title":"Updated Review on Treatment of Atopic Dermatitis","volume":"33","author":"Carrascosa","year":"2023","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Furue, M., and Furue, M. (2021). Ox40l\u2013Ox40 Signaling in Atopic Dermatitis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122578"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/bjd\/ljae230","article-title":"The Role of OX40 Ligand\/OX40 Axis Signalling in Atopic Dermatitis","volume":"191","author":"Croft","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Marfil-Cant\u00f3n, M., Prados-Carmona, A., Cebolla-Verdugo, M., Husein-ElAhmed, H., Campos, F., and Ruiz-Villaverde, R. (2024). Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226925"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an Anti-OX40, Improves Skin Gene Signatures and Clinical Scores in Patients with Atopic Dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.jacig.2023.100195","article-title":"Phase 2b Randomized Trial of OX40 Inhibitor Telazorlimab for Moderate-to-Severe Atopic Dermatitis","volume":"3","author":"Rewerska","year":"2024","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"L\u00e9, A.M., and Torres, T. (2022). OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis\u2014Focus on Rocatinlimab and Amlitelimab. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122753"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, Tolerability and Efficacy of Repeated Intravenous Infusions of KHK4083, a Fully Human Anti-OX40 Monoclonal Antibody, in Japanese Patients with Moderate to Severe Atopic Dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_117","unstructured":"(2025, November 16). Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis. Available online: https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2021\/e20210218_01.html."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"AB123","DOI":"10.1016\/j.jaad.2022.06.525","article-title":"Treatment with Amlitelimab (KY1005, SAR445229): A Novel Nondepleting Anti-OX40Ligand (OX40L) MAb Reduces IL-13 Serum Levels in a Phase 2a Randomized Placebo-Controlled Trial in Patients with Moderate to Severe Atopic Dermatitis","volume":"87","author":"Weidinger","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and Efficacy of Amlitelimab, a Fully Human Nondepleting, Noncytotoxic Anti-OX40 Ligand Monoclonal Antibody, in Atopic Dermatitis: Results of a Phase IIa Randomized Placebo-Controlled Trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 Randomized Clinical Trial of Astegolimab in Patients with Moderate to Severe Atopic Dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ced\/llad460","article-title":"CD1a and Skin T Cells: A Pathway for Therapeutic Intervention","volume":"49","author":"Ye","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41401-020-0412-8","article-title":"Blockage of Sphingosine-1-Phosphate Receptor 2 Attenuates 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis in Mice","volume":"41","author":"Park","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9230","DOI":"10.1038\/s41467-024-53384-1","article-title":"The Regulatory T Cell-Selective Interleukin-2 Receptor Agonist Rezpegaldesleukin in the Treatment of Inflammatory Skin Diseases: Two Randomized, Double-Blind, Placebo-Controlled Phase 1b Trials","volume":"15","author":"Silverberg","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Prados-Carmona, A., Navarro-Trivi\u00f1o, F.J., Husein-ElAhmed, H., and Ruiz-Villaverde, R. (2025). Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041291"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2304630","DOI":"10.1080\/09546634.2024.2304630","article-title":"Complete Response of Extensive Alopecia Areata Refractory to Baricitinib after Five Months of Treatment with Upadacitinib","volume":"35","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_126","first-page":"e24","article-title":"Could Baricitinib Be a Safe and Effective Therapeutic Alternative for Incoercible Pruritus in Patients with Dermatitis Herpetiformis?","volume":"63","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Bizzarri, F., Ruiz-Villaverde, R., Morales-Garrido, P., Ruiz-Carrascosa, J.C., Cebolla-Verdugo, M., Prados-Carmona, A., Rodriguez-Troncoso, M., and Raya-Alvarez, E. (2024). JAKinhibs in Psoriatic Disease: Analysis of the Efficacy\/Safety Profile in Daily Clinical Practice. Diagnostics, 14.","DOI":"10.20944\/preprints202403.0239.v1"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus Kinase\/SYK Inhibition (ASN002) Suppresses Inflammation and Improves Epidermal Barrier Markers in Patients with Atopic Dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The Oral Janus Kinase\/Spleen Tyrosine Kinase Inhibitor ASN 002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-severe Atopic Dermatitis: Results from a Randomized Double-blind Placebo-controlled Study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults with Phototherapy and Systemic Therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"He, Q., Xie, X., Chen, Q., Li, W., Song, Z., Wang, X., Ma, X., Zeng, J., and Guo, J. (2024). Janus Kinase Inhibitors in Atopic Dermatitis: An Umbrella Review of Meta-Analyses. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1342810"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK Inhibitors in the Treatment of Atopic Dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1159\/000518541","article-title":"Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"238","author":"Li","year":"2022","journal-title":"Dermatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"adv00764","DOI":"10.2340\/actadv.v102.2075","article-title":"Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"102","author":"Sedeh","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.19426","article-title":"The Safety of Systemic Janus Kinase Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"38","author":"Yoon","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","article-title":"The Safety of Systemic Janus Kinase Inhibitors in Atopic Dermatitis: A Systematic Review and Network Meta-Analysis","volume":"78","author":"Alves","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ijd.17501","article-title":"Infection Risk with JAK Inhibitors in Dermatoses: A Meta-analysis","volume":"64","author":"Ireland","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","article-title":"Comparative Safety of Oral Janus Kinase Inhibitors versus Dupilumab in Patients with Atopic Dermatitis: A Population-Based Cohort Study","volume":"154","author":"Tsai","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e22014","DOI":"10.1016\/j.heliyon.2023.e22014","article-title":"Short-Term Efficacy and Safety of Biologics and Janus Kinase Inhibitors for Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the Complexities of Atopic Dermatitis: Shifting Paradigms in Treatment Approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/14712598.2013.758708","article-title":"New Era of Biologic Therapeutics in Atopic Dermatitis","volume":"13","author":"Dhingra","year":"2013","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clindermatol.2017.03.012","article-title":"Systemic Therapies in Atopic Dermatitis: The Pipeline","volume":"35","year":"2017","journal-title":"Clin. Dermatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic Dermatitis Yardstick: Practical Recommendations for an Evolving Therapeutic Landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","article-title":"Placebo Responses in Randomized Controlled Trials for Systemic Therapy in Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative Efficacy and Safety of Systemic Therapies Used in Moderate-to-severe Atopic Dermatitis: A Systematic Literature Review and Network Meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic Treatments for Atopic Dermatitis (Eczema): Systematic Review and Network Meta-Analysis of Randomized Trials","volume":"152","author":"Chu","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.19897","article-title":"Dupilumab Treatment in Patients with Atopic Dermatitis: A Comparative Cohort Study between the Netherlands and Japan Shows a Discrepancy in Patient-reported Outcome Measures","volume":"185","author":"Fujimoto","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jid.2024.08.034","article-title":"A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice","volume":"145","author":"Schneeweiss","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"113383","DOI":"10.1016\/j.intimp.2024.113383","article-title":"Comparative Effectiveness of Upadacitinib versus Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study","volume":"143","author":"Yang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","article-title":"Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors","volume":"25","author":"Kim","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Zhang, J., Li, W., Gong, M., Gu, Y., Zhang, H., Dong, B., Guo, Q., Pang, X., Xiang, Q., and He, X. (2023). Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Inflammatory Immune Diseases: A Systematic Review and Meta-Analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1189389"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12016-025-09075-w","article-title":"Atopic Dermatitis beyond Eczema: A Review on Its Systemic Impact through Pruritus and Associated Comorbidities","volume":"68","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","article-title":"Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-Analysis","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/bjd\/ljad393","article-title":"Comparing Binary Efficacy Outcomes for Systemic Immunomodulatory Treatments for Atopic Dermatitis in a Living Systematic Review and Network Meta-Analysis","volume":"190","author":"Drucker","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","article-title":"Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review","volume":"14","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s13555-024-01166-4","article-title":"Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review","volume":"14","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e70045","DOI":"10.1111\/pai.70045","article-title":"Comparative Efficacy of Biologics and Small Molecule Drugs in Treating Pediatric Atopic Dermatitis in Patients Aged 2\u201318\u2009Years: A 12\u201316\u2009Week Network Meta-analysis of Randomized Controlled Trials","volume":"36","author":"Yong","year":"2025","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ced\/llad129","article-title":"Early Improvements in Signs and Symptoms Predict Clinical Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis","volume":"48","author":"Bieber","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Ibba, L., Falcidia, C., Di Giulio, S., Bianco, M., Valenti, M., Facheris, P., Narcisi, A., Costanzo, A., and Gargiulo, L. (2025). Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092953"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"de Bruin-Weller, M.S., Boesjes, C.M., Achten, R.A., Beck, L.A., Irvine, A.D., Vestergaard, C., de Graaf, M., van Wijk, F., Bakker, D.S., and Weidinger, S. (Allergy, 2025). Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions, Allergy, online ahead of print.","DOI":"10.1111\/all.70061"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/jdv.19669","article-title":"Baricitinib Treatment Rapidly Improves the Four Signs of Atopic Dermatitis Assessed by Eczema Area and Severity Index (EASI) Clinical Subscores","volume":"38","author":"Wollenberg","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and Efficacy of Upadacitinib in Combination with Topical Corticosteroids in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis (AD Up): Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1089\/derm.2024.0014","article-title":"Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China","volume":"35","author":"Zhu","year":"2024","journal-title":"Dermatitis"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","article-title":"Guidelines of Care for the Management of Atopic Dermatitis: Section 4. Prevention of Disease Flares and Use of Adjunctive Therapies and Approaches","volume":"71","author":"Sidbury","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Guo, B.-C., Wu, K.-H., Chen, C.-Y., Lin, W.-Y., Chang, Y.-J., Lin, M.-J., and Wu, H.-P. (2024). Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021316"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"190","DOI":"10.18176\/jiaci.0672","article-title":"Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis: A Meta-Analysis of Randomized Clinical Trials","volume":"31","author":"Xiao","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis","volume":"382","author":"Yosipovitch","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: A New Key Player in Dermatology and Beyond","volume":"141","author":"Ruzicka","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses","volume":"81","author":"Roh","year":"2021","journal-title":"Drugs"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Orfali, R.L., and Aoki, V. (2023). Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020577"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s13555-022-00782-2","article-title":"Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments","volume":"12","author":"Bewley","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14712598.2021.1958777","article-title":"Therapeutic Potential of Biologics in Prurigo Nodularis","volume":"22","author":"Bieber","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ad.2021.12.014","article-title":"Nemolizumab: Un Innovador Tratamiento Biol\u00f3gico Para El Control de La Interleuquina 31 (IL-31) Clave En La Dermatitis At\u00f3pica y El Prurigo Nodular","volume":"113","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s11096-023-01569-x","article-title":"Topical Janus Kinase Inhibitors in Atopic Dermatitis: A Safety Network Meta-Analysis","volume":"45","author":"Alves","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults with Topical Therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/all.14870","article-title":"A Mathematical Model to Identify Optimal Combinations of Drug Targets for Dupilumab Poor Responders in Atopic Dermatitis","volume":"77","author":"Miyano","year":"2022","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00403-024-03319-z","article-title":"Interleukin-1\u03b1 Inhibitor Bermekimab in Patients with Atopic Dermatitis: Randomized and Nonrandomized Studies","volume":"316","author":"Simpson","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"ljae266.052","DOI":"10.1093\/bjd\/ljae266.052","article-title":"678-Patient-Reported Outcomes for GSK1070806, an Anti-IL-18 Monoclonal Antibody: A Phase 1b, Randomised, Double-Blind, Parallel-Group Placebo-Controlled Study of Patients with Atopic Dermatitis","volume":"191","author":"Ghafoori","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.anai.2024.03.002","article-title":"Bruton\u2019s Tyrosine Kinase Inhibition for the Treatment of Allergic Disorders","volume":"133","author":"Lin","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Roufosse, F. (2018). Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00049"},{"key":"ref_184","first-page":"e1211","article-title":"Lack of Effect of Benralizumab on Signs and Symptoms of Moderate-to-severe Atopic Dermatitis: Results from the Phase 2 Randomized, Double-blind, Placebo-controlled HILLIER Trial","volume":"37","author":"Bahadori","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ijd.13353","article-title":"Omalizumab for Atopic Dermatitis: Case Series and a Systematic Review of the Literature","volume":"56","author":"Holm","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/pai.12584","article-title":"Treating IgE-mediated Diseases via Targeting IgE-expressing B Cells Using an Anti-C\u03b5mX Antibody","volume":"27","author":"Liour","year":"2016","journal-title":"Pediatr. Allergy Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11487\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:52:27Z","timestamp":1764244347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":186,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262311487"],"URL":"https:\/\/doi.org\/10.3390\/ijms262311487","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}